Purchase this article with an account.
C.A. Samson, K.M. Narayana, P. Latkany, S. Schwartzman; Infliximab in the Treatment of Chronic Non–infectious Ocular Inflammation . Invest. Ophthalmol. Vis. Sci. 2005;46(13):2837.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose: To evaluate the efficacy and safety of infliximab in the treatment of chronic non–infectious ocular inflammation Methods: Charts of patients with chronic non–infectious ocular inflammation treated with infliximab were reviewed retrospectively Results: Five patients with uveitis and two patients with scleritis treated with infliximab were seen between 2000 and 2004. The mean patient age was 42 years (range: 12–70). Five patients were female. The mean follow–up time was 21.5 months. Ocular inflammation was controlled in five patients. Reduction of oral presdnisone was possible in 3 patients. No adverse reactions related to infliximab occurred in the follow–up period. Conclusions: Infliximab can be an effective treatment for non–infectious inflammation, and can allow reduction in the required steroid dose. There were no serious side–effects in this pilot retrospective case series.
This PDF is available to Subscribers Only